Important corroboration of our findings, tumor-intrinsic NR2F6, came from independent scRNA-seq analysis of human melanoma specimens: NR2F6, NACC1, and FKBP10 expression in malignant melanoma cells was significantly higher in samples from patients that are nonresponsive to anti–PD-1–based ICT (Fig. 7C). This evidence concerns the gene NACC1 and melanoma.